William Blair analyst Matt Larew has maintained their neutral stance on AMED stock, giving a Hold rating on April 24.
Matt Larew has given his Hold rating due to a combination of factors surrounding the recent divestiture announcement by Amedisys. The divestiture, involving the sale of Amedisys/UnitedHealth assets to BrightSpring and Pennant Group, marks a significant milestone towards the anticipated closure of the deal. Larew expects the shares to respond positively to this development, as the acquirers are well-established entities with substantial operational experience.
Despite the positive outlook on the deal’s completion, Larew maintains a cautious stance, reflected in the Hold rating. The current trading price of Amedisys shares, which is close to the valuation of comparable companies, suggests limited downside risk even if the deal does not go through. The 6% discount on the expected closing date also supports a Market Perform rating, indicating that while the stock is not expected to outperform, it is not likely to underperform significantly either.